Early research (Phase 1)Study completedNCT01034475
What this trial is testing
Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies
Who this might be right for
Advanced Hematologic Malignancies
Wake Forest University Health Sciences 26